Acute Myelogenous Leukemia
222
9
15
136
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
76 trials with published results (34%)
Research Maturity
136 completed trials (61% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
19.8%
44 terminated out of 222 trials
75.6%
-11.0% vs benchmark
6%
14 trials in Phase 3/4
56%
76 of 136 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 136 completed trials
Clinical Trials (222)
Biology Studies of Hematologic Cancers
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
LILRB4 STAR-T Cell Therapy for Monocytic Leukemia
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Resiliency in Older Adults Undergoing Bone Marrow Transplant
Epigenetic Reprogramming in Relapse/Refractory AML
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)